Will CE's net leverage ratio exceed 7.0x at any quarter-end through Q4 2026?
Current Prediction
Why This Question Matters
Net leverage above 7.0x would indicate covenant proximity, would constrain refinancing flexibility, and would shift FUNDING_FRAGILITY from ELEVATED toward STRAINED. CE's revolver was extended to 2030 in Aug 2025, which signaled bank confidence at senior level despite junk rating. A leverage breach to 7.0x against extended bank covenants would force corrective action — either accelerated divestitures, equity issuance, or bond retap at higher spread. This is the inverse of the recovery thesis; a clean YE2026 leverage at 5.0-5.5x would confirm execution. Stress-scanner and roadkill-radar both flag 7.0x as the critical threshold.
Prediction Distribution
Individual Predictions(9 runs)
Math: $11B net debt / 7.0x = $1.57B EBITDA TTM. Current TTM ~$1.7-1.9B. To breach, EBITDA needs to fall to $1.5B sustained — requires 2 quarters at $350-400M each. Plausible but tail scenario. Cycle extension scenario (10-15%) is the primary path to this outcome. Net debt direction: declining $650-750M annually from FCF, which actively shrinks leverage even at flat EBITDA. With FCF discipline holding, leverage probably moves to 5.0-5.5x by YE2026 in base case. 4-quarter window adds chances for transient EBITDA dip. ~15-20%.
Bank confidence at senior level (revolver extension to 2030) implies leverage trajectory is acceptable. For 7.0x breach we need EBITDA collapse + working capital drain or M&A surprise. Mgmt has eliminated dividend, no buybacks, divestitures are net-debt-reducing. Most paths to leverage spike are blocked. ~15%.
The committee anchors structural-decline counterfactual at 8-12% with mid-cycle EBITDA $1.8-2.0B. If structural, leverage walks to 5.5-6.1x not 7.0x. So even structural decline doesn't directly produce 7.0x without compounding factors (impairment + working capital + cycle extension). 4-quarter window: any-quarter probability 15-20% given compounding tail. ~18%.
Quarterly TTM EBITDA can spike low transiently due to seasonal Q1 + working capital. Combined with any large impairment (Sadara-type EM goodwill), single-quarter print at 7.0x is plausible. Mgmt would aggressively message past optical leverage. ~20%.
5.5-6.5x current. Cycle-extension scenario probability ~10-15%. EM impairment probability material (mgmt strategic review). Adding factors: net 18%.
Active deleveraging from FCF is the dominant trajectory. ~15-18% probability of leverage breach assumes most factors aligning negatively. Base case clearly trends lower. ~16%.
Cycle extension prob 10-15%. EM impairment overlay. 4-quarter chances. ~18%.
Bank confidence + active deleveraging + dividend cut all point to leverage decline. 7.0x is tail event. ~15%.
Compounding scenarios: cycle extension + impairment + working capital build. Probability ~15-20%. ~18%.
Resolution Criteria
Resolves YES if CE's reported net debt / trailing-twelve-month adjusted EBITDA ratio at any quarter-end (Q1, Q2, Q3, or Q4 2026) exceeds 7.0x, as disclosed in earnings release, investor presentation, or 10-Q filing. Resolves NO if all four quarter-ends print at or below 7.0x.
Resolution Source
CE quarterly earnings releases, investor presentations, 10-Q and 10-K filings
Source Trigger
Net leverage >7.0x
Full multi-lens equity analysis